[Treatment of prostatic carcinoma in an advanced stage. Our experience]. / Il trattamento del carcinoma prostatico in stadio avanzato. Nostra esperienza.

The authors report the results of a retrospective study regarding 214 patients (mean age 73, smallest follow-up 6 months, greatest 70 months, average 42 months) affected by advanced prostatic cancer histologically demonstrated, observed from January 1983 to December 1990 and subject to hormonal treatment. They particular compared so-called "total androgenic suppression" (Gn-RH analogous or orchiectomy plus antiandrogen) with the "partial androgenic suppression" (Gn-RH analogous or orchiectomy). The authors report the results of the treatment regarding the subjective and the objective response, evaluated with NPCP criteria. Moreover the actuarial aspects of response and survival curves of two groups of patients are compared. The authors conclude that total compared to partial androgenic suppression does not offer significant advantages as regards to objective response and present their current treatment of advanced prostatic cancer.

[Use of the monoclonal antibody KI-67 in the study of the proliferative activity of urologic tumors. Preliminary data]. / L'emploi de l'anticorps monoclonal KI-67 dans l'étude de l'activité proliférative des tumeurs urologiques. Données préliminaires.

The authors report the preliminary data of a study on the proliferative activity in urologic cancers. They use the monoclonal antibody KI-67 which can find out a nuclear antigen present only in cells in proliferative phase. They describe the methodology and report the results concerning 12 cancers of the kidney, 17 of the bladder, 17 of the prostate and 2 of the testicle. The most interesting results were obtained in the study of bladder cancer where they could pick out, in the context of the cancers with grading G2, a sub-group with proliferative characteristics similar to those of cancers G3 and vice-versa. They also obtained important results in the study of prostate cancer in hormonal therapy, as they could demonstrate the disappearance of the proliferative activity in patients responding clinically to the treatment.